Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Exclusion Criteria

• •Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
• •Significant liver disease in addition to hepatitis C
• •Decompensated liver disease medical history or current clinical features
• •Histologic evidence of hepatic cirrhosis
• •Concurrent clinically significant medical diagnosis (other than CHC)
• •Concurrent social conditions (e.g. drugs of abuse, alcohol excess, poor living accommodation)
• •Clinically significant illness within 30 days preceding entry into the study
• •Participated in an investigational drug study within 30 days or 5 half-lives, whichever is longer, prior to the start of study medication
• •History of clinically significant allergic drug reactions